Orthocell minimises US tariff threat as Australian biotechs play down impact

Orthocell (ASX:OCC) has joined a cohort of Australian life sciences companies seeking to calm investor nerves over looming US tariff measures, arguing that its business will remain largely untouched even as Washington signals a tougher stance on imported pharmaceuticals. …